All In Biotech

Drug Trial Radar · NCT05579327

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study

Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20

Actual

Start

Jul 21, 2023

Primary completion

Jul 22, 2025

Study completion Sep 3, 2025

Sponsor

Sponsor type
Industry
Collaborators
Premier Research; Egetis Therapeutics AB (publ)
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized phase 3 multicenter placebo-controlled study in at least 16 evaluable male participants diagnosed with MCT8 deficiency. Male participants, from 4 years of age (at randomization) and having demonstrated stable maintenance treatment with tiratricol, will be randomized to receive placebo or tiratricol for 30 days or until reaching the rescue criterion (serum total triiodothyronine \[T3\] \> upper limit of normal \[ULN\] of the participant's normal range, for a sample collected during the 30-day Randomized Treatment Period). The research hypothesis to be tested is that, for participants in the placebo group, removal of tiratricol will lead to an increase of serum total T3 concentration, measured by liquid chromatography with tandem mass spectrometry (LC/MS/MS), above the ULN and requirement of rescue treatment with tiratricol, compared to those who continue to receive tiratricol.

Conditions

  • Monocarboxylate Transporter 8 Deficiency
  • Allan-Herndon-Dudley Syndrome

Interventions

  • TiratricolDrug

    Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.

  • PlaceboDrug

    Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of change from baseline in serum total T3 (ln-transformed) during the 30-day double-blind Randomized Treatment PeriodTime frame: Baseline to Day 30
  2. Proportion of participants who meet the rescue criterion (serum total T3 > ULN) during the 30-day double-blind Randomized Treatment PeriodTime frame: Baseline to Day 30

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Rare Disease Research, LLC

    Kissimmee, Florida

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • SSM Health Cardinal Glennon Children's Hospital

    St Louis, Missouri

  • Rare Disease Research, LLC

    Hillsborough, North Carolina

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Tranquil Clinical and Research Consulting Services

    Webster, Texas

  • Erasmus MC

    Rotterdam, Netherlands

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.